VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate in...

Related Keywords

United States ,Washington ,American , ,World Vaccine Congress Washington ,American Society Of Clinical Oncology ,Vaccines Inc ,Drug Administration ,Clinical Oncology ,Study Design ,